Arnauld Villers

List of Publications by Citations

180 papers	15,875 citations	53 h-index	125 g-index
210 ext. papers	19,000 ext. citations	5.9 avg, IF	5.92 L-index

#	Paper	IF	Citations
180	Screening and prostate-cancer mortality in a randomized European study. *New England Journal of Medicine*, **2009**, 360, 1320-8	59.2	2828
179	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *New England Journal of Medicine*, **2018**, 378, 1767-1777	59.2	1250
178	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. *Lancet, The*, **2014**, 384, 2027-35	40	910
177	Prostate-cancer mortality at 11 years of follow-up. *New England Journal of Medicine*, **2012**, 366, 981-90	59.2	875
176	Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. *European Urology*, **2015**, 68, 1045-53	10.2	537
175	Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. *European Urology*, **2011**, 59, 477-94	10.2	537
174	Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. *European Urology*, **2013**, 63, 125-40	10.2	425
173	A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. *European Urology*, **2010**, 57, 179-92	10.2	328
172	Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. *Journal of Urology*, **2006**, 176, 2432-7	2.5	323
171	Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. *European Urology*, **2013**, 64, 544-52	10.2	309
170	Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. *BJU International* , **2011**, 108, E171-8	5.6	305
169	Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. *Radiology*, **2013**, 268, 461-9	20.5	294
168	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. *Journal of Clinical Oncology*, **2019**, 37, 2974-2986	2.2	285
167	Quality-of-life effects of prostate-specific antigen screening. *New England Journal of Medicine*, **2012**, 367, 595-605	59.2	279
166	The role of perineural space invasion in the local spread of prostatic adenocarcinoma. *Journal of Urology*, **1989**, 142, 763-8	2.5	278
165	Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. *European Urology*, **2015**, 67, 627-36	10.2	234
164	Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. *Cancer*, **1992**, 70, 2313-8	6.4	199

163	Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. *Urology*, **2009**, 74, 1094-9	1.6	190
162	Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. *BJU International*, **2009**, 104, 1436-40	5.6	178
161	New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. *European Urology*, **2017**, 71, 17-34	10.2	165
160	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. *Lancet Oncology, The*, **2016**, 17, 153-163	21.7	164
159	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. *European Urology*, **2019**, 76, 43-51	10.2	163
158	Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. *European Urology*, **2015**, 67, 771-7	10.2	163
157	A novel robotic system for single-port urologic surgery: first clinical investigation. *European Urology* , **2014**, 66, 1033-43	10.2	150
156	A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy: An Update. *European Urology*, **2016**, 70, 301-11	10.2	149
155	Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). *European Urology*, **2009**, 56, 584-91	10.2	146
154	Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. *European Radiology*, **2009**, 19, 470-80	8	130
153	Combined multiparametric MRI and targeted biopsies improve anterior prostate cancer detection, staging, and grading. *Urology*, **2011**, 78, 1356-62	1.6	117
152	Image Guided Focal Therapy for Magnetic Resonance Imaging Visible Prostate Cancer: Defining a 3-Dimensional Treatment Margin Based on Magnetic Resonance Imaging Histology Co-Registration Analysis. *Journal of Urology*, **2015**, 194, 364-70	2.5	112
151	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. *Annals of Internal Medicine*, **2017**, 167, 449-455	8	108
150	Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. *Journal of Magnetic Resonance Imaging*, **2013**, 37, 48-58	5.6	106
149	Invasion of Denonvilliers' fascia in radical prostatectomy specimens. *Journal of Urology*, **1993**, 149, 793-8	2.5	102
148	Microcarcinoma in the prostate: its association with duct-acinar dysplasia. *Human Pathology*, **1991**, 22, 644-52	3.7	101
147	Novel tools to improve patient selection and monitoring on active surveillance for low-risk prostate cancer: a systematic review. *European Urology*, **2014**, 65, 1023-31	10.2	98
146	Focal High Intensity Focused Ultrasound of Unilateral Localized Prostate Cancer: A Prospective Multicentric Hemiablation Study of 111 Patients. *European Urology*, **2017**, 71, 267-273	10.2	95

145	Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. *BJU International*, **2012**, 109, 1636-47	5.6	88
144	Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. *Histopathology*, **2010**, 56, 180-7	7.3	86
143	Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology. *Prostate*, **2009**, 69, 105-13	4.2	84
142	Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance. *Current Opinion in Urology*, **2009**, 19, 274-82	2.8	83
141	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. *World Journal of Urology*, **2012**, 30, 149-55	4	81
140	Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. *European Urology*, **2015**, 68, 885-90	10.2	77
139	Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. *BJU International*, **2011**, 108, 1074-85	5.6	75
138	A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. *BJU International*, **2012**, 110, 812-20	5.6	72
137	The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. *Clinical Cancer Research*, **2010**, 16, 4374-81	12.9	72
136	Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. *BJU International*, **2015**, 116, 888-96	5.6	65
135	MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/Ecatenin pathway and interaction with SNAIL promoter. *Cancer Letters*, **2014**, 346, 225-36	9.9	64
134	Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. *European Urology*, **2011**, 60, 366-73	10.2	64
133	A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. *BMC Cancer*, **2010**, 10, 635	4.8	64
132	Computer-assisted diagnosis of prostate cancer using DCE-MRI data: design, implementation and preliminary results. *International Journal of Computer Assisted Radiology and Surgery*, **2009**, 4, 1-10	3.9	63
131	Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology. *Prostate*, **2009**, 69, 276-82	4.2	63
130	Management of Node Only Recurrence after Primary Local Treatment for Prostate Cancer: A Systematic Review of the Literature. *Journal of Urology*, **2015**, 194, 983-8	2.5	60
129	Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies. *Journal of Urology*, **2015**, 194, 350-6	2.5	60
128	Renal cell carcinoma with rhabdoid features: an aggressive neoplasm with overexpression of p53. *Archives of Pathology and Laboratory Medicine*, **2007**, 131, 102-6	5	55

127	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. *World Journal of Urology*, **2012**, 30, 181-7	4	50
126	The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. *International Journal of Cancer*, **2010**, 126, 2387-93	7.5	49
125	Renal vein ostium wall invasion of renal cell carcinoma with an inferior vena cava tumor thrombus: prediction by renal and vena caval vein diameters and prognostic significance. *Journal of Urology*, **2008**, 179, 450-4; discussion 454	2.5	49
124	Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. *BJU International*, **2012**, 110, 517-23	5.6	47
123	Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. *Urology*, **2011**, 78, 607-13	1.6	46
122	Mucinous differentiation in prostatic adenocarcinoma. *Human Pathology*, **1991**, 22, 979-88	3.7	46
121	Ultrasound anatomy of the prostate: the normal gland and anatomical variations. *Journal of Urology*, **1990**, 143, 732-8	2.5	44
120	Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. *World Journal of Urology*, **2015**, 33, 1669-76	4	43
119	Imaging of organ-confined prostate cancer: functional ultrasound, MRI and PET/computed tomography. *Current Opinion in Urology*, **2009**, 19, 168-76	2.8	43
118	The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. *Cancer*, **2018**, 124, 1197-1206	6.4	41
117	Cancer-specific and non-cancer-related mortality rates in European patients with T1a and T1b renal cell carcinoma. *BJU International*, **2009**, 103, 894-8	5.6	40
116	Target ablation--image-guided therapy in prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 912-23	2.8	38
115	Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. *BJU International*, **2014**, 114, 698-707	5.6	38
114	Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. *Nature Reviews Urology*, **2017**, 14, 312-322	5.5	37
113	The role of MRI-targeted and confirmatory biopsies for cancer upstaging at selection in patients considered for active surveillance for clinically low-risk prostate cancer. *World Journal of Urology*, **2014**, 32, 951-8	4	37
112	Endoluminal occlusion of the inferior vena cava in renal cell carcinoma with retro- or suprahepatic caval thrombus. *BJU International*, **2006**, 97, 1216-20	5.6	35
111	MUC6 is a marker of seminal vesicle-ejaculatory duct epithelium and is useful for the differential diagnosis with prostate adenocarcinoma. *American Journal of Surgical Pathology*, **2003**, 27, 519-21	6.7	34
110	Modified extrafascial radical retropubic prostatectomy technique decreases frequency of positive surgical margins in T2 cancers . *European Urology*, **2000**, 38, 64-73	10.2	34

109	Surveillance after prostate focal therapy. *World Journal of Urology*, **2019**, 37, 397-407	4	33
108	Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy. *Journal of Urology*, **2013**, 190, 1750-6	2.5	33
107	Focal laser ablation of prostate cancer: definition, needs, and future. *Advances in Urology*, **2012**, 2012, 589160	1.6	33
106	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. *European Urology*, **2019**, 75, 523-531	10.2	33
105	A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. *BJU International*, **2009**, 103, 899-904; discussion 904	5.6	32
104	The efficacy of intrathecal morphine with or without clonidine for postoperative analgesia after radical prostatectomy. *Anesthesia and Analgesia*, **2009**, 108, 1954-7	3.9	32
103	Renal cell carcinoma associated with tumor thrombus in the inferior vena cava: surgical strategies. *Annals of Vascular Surgery*, **2005**, 19, 522-8	1.7	32
102	SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. *World Journal of Urology*, **2019**, 37, 61-83	4	31
101	Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature. *Cancer Treatment Reviews*, **2011**, 37, 366-72	14.4	31
100	Multiparametric MRI-targeted TRUS prostate biopsies using visual registration. *BioMed Research International*, **2014**, 2014, 819360	3	28
99	Focal laser interstitial thermotherapy (LITT) at 980 nm for prostate cancer: treatment feasibility in Dunning R3327-AT2 rat prostate tumour. *BJU International*, **2012**, 109, 452-8	5.6	28
98	Multimodality magnetic resonance imaging of prostate cancer. *Journal of Endourology*, **2010**, 24, 677-84	2.7	27
97	Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin. *Molecular Cancer Research*, **2011**, 9, 914-24	6.6	27
96	Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial. *Journal of Urology*, **2018**, 199, 147-154	2.5	26
95	Partial Prostatectomy for Anterior Cancer: Short-term Oncologic and Functional Outcomes. *European Urology*, **2017**, 72, 333-342	10.2	26
94	Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 281-4	2.8	25
93	How are we going to train a generation of radiologists (and urologists) to read prostate MRI?. *Current Opinion in Urology*, **2015**, 25, 522-35	2.8	25
92	Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. *World Journal of Urology*, **2014**, 32, 185-91	4	23

91	Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy. *European Urology*, **2020**, 78, 583-591	10.2	23
90	Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 1024-30	2.8	22
89	Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. *European Urology*, **2017**, 71, 534-542	10.2	21
88	Race affects access to nephrectomy but not survival in renal cell carcinoma. *BJU International*, **2009**, 103, 889-93	5.6	21
87	Dynamic Contrast-Enhanced MRI for Preoperative Identification of Localised Prostate Cancer. *European Urology Supplements*, **2007**, 6, 525-532	0.9	20
86	Testicular natural killer T-cell lymphoma. *International Journal of Urology*, **2005**, 12, 223-4	2.3	19
85	The use of partial nephrectomy: results from a contemporary national prospective multicenter study. *World Journal of Urology*, **2015**, 33, 33-40	4	18
84	External validation of outcome prediction model for ureteral/renal calculi. *Journal of Urology*, **2006**, 175, 575-9	2.5	18
83	Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.. *Journal of Clinical Oncology*, **2019**, 37, 687-687	2.2	18
82	Modernizing the diagnostic and decision-making pathway for prostate cancer. *Clinical Cancer Research*, **2014**, 20, 6254-7	12.9	16
81	Celiac axis and superior mesenteric artery: danger zone for left nephrectomy. *Journal of Endourology*, **2008**, 22, 2571-4	2.7	16
80	Microarray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages. *BJU International*, **2014**, 113, 333-42	5.6	15
79	Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. *World Journal of Urology*, **2014**, 32, 1331-8	4	14
78	Extraperitoneal endosurgical lymphadenectomy with insufflation in the staging of bladder and prostate cancer. *Journal of Endourology*, **1993**, 7, 229-35	2.7	14
77	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. *Cancer*, **2016**, 122, 3386-3393	6.4	14
76	Prostate cancer heterogeneity: texture analysis score based on multiple magnetic resonance imaging sequences for detection, stratification and selection of lesions at time of biopsy. *BJU International*, **2019**, 124, 76-86	5.6	14
75	Predictive factors of urinary incontinence after holmium laser enucleation of the prostate: a multicentric evaluation. *World Journal of Urology*, **2021**, 39, 143-148	4	14
74	Multiparametric prostate MRI: technical conduct, standardized report and clinical use. *Minerva Urology and Nephrology*, **2018**, 70, 9-21	2.3	14

73	Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. *European Urology*, **2014**, 66, 655-63	10.2	13
72	Limited prognostic value of tumor necrosis in patients with renal cell carcinoma. *Urology*, **2010**, 75, 1378-84	1.84	13
71	Results of endoluminal occlusion of the inferior vena cava during radical nephrectomy and thrombectomy. *European Urology*, **2008**, 54, 778-83	10.2	13
70	Role of preoperative positive apical biopsies in the prediction of specimen-confined prostate cancer after radical retropubic prostatectomy: a multi-institutional study. *European Urology*, **2000**, 37, 281-8	10.2	13
69	Transrectal Ultrasound Appearance of Transitional Cell Carcinoma Involving the Prostate. *Journal of Urology*, **1990**, 143, 953-956	2.5	13
68	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. *European Urology*, **2019**, 76, 693-702	10.2	12
67	Seasonality of serum prostate-specific antigen levels: a population-based study. *European Urology*, **2007**, 52, 708-14	10.2	12
66	TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. *Cancer Letters*, **2018**, 438, 32-43	9.9	12
65	Robot-assisted partial prostatectomy for anterior prostate cancer: a step-by-step guide. *BJU International*, **2017**, 119, 968-974	5.6	11
64	Quantified analysis of histological components and architectural patterns of gleason grades in apparent diffusion coefficient restricted areas upon diffusion weighted MRI for peripheral or transition zone cancer locations. *Journal of Magnetic Resonance Imaging*, **2017**, 46, 1786-1796	5.6	11
63	Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 495.e1-7	2.8	11
62	A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality. *European Urology*, **2014**, 66, 401-3	10.2	11
61	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. *European Urology Oncology*, **2020**, 3, 80-91	6.7	11
60	MRI and surveillance. *Current Opinion in Urology*, **2012**, 22, 231-6	2.8	10
59	Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-color in situ hybridization and immunohistochemistry. *Applied Immunohistochemistry and Molecular Morphology*, **2012**, 20, 363-6	1.9	10
58	A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol. *BMJ Open*, **2017**, 7, e017863	3	9
57	Prostate cancer computer-assisted diagnosis software using dynamic contrast-enhanced MRI. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society*, **2007**, 2007, 5567-70		9
56	Low-risk prostate cancer selected for active surveillance with negative MRI at entry: can repeat biopsies at 1 year be avoided? A pilot study. *World Journal of Urology*, **2019**, 37, 253-259	4	8

55	Epidemiologie du cancer de la prostate. *Medecine Nucleaire*, **2008**, 32, 2-4	0.1	8
54	Bladder cancer arising in a spina bifida patient. *Urology*, **1999**, 54, 923	1.6	8
53	Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results. *Journal of Urology*, **2021**, 205, 725-731	2.5	8
52	Targeted Anterior Gland Focal Therapy-a Novel Treatment Option for a Better Defined Disease. *Current Urology Reports*, **2016**, 17, 69	2.9	8
51	Understanding the pathological implications of MRI: application to focal therapy planning. *Current Opinion in Urology*, **2015**, 25, 198-204	2.8	7
50	Risk of biochemical recurrence based on extent and location of positive surgical margins after robot-assisted laparoscopic radical prostatectomy. *BMC Cancer*, **2018**, 18, 1291	4.8	7
49	Beyond transrectal ultrasound-guided prostate biopsies: available techniques and approaches. *World Journal of Urology*, **2019**, 37, 419-427	4	6
48	ESUR prostate MR guidelines. Author reply. *European Radiology*, **2013**, 23, 2322-3	8	6
47	3D Registration of mpMRI for Assessment of Prostate Cancer Focal Therapy. *Academic Radiology*, **2017**, 24, 1544-1555	4.3	6
46	Polytetrafluoroethylene expanded prosthesis as replacement of the inferior vena cava in renal cell carcinoma with caval thrombus. *International Journal of Urology*, **2014**, 21, 448-52	2.3	6
45	Robotic-assisted Laparoscopic Bilateral Nerve Sparing and Apex Preserving Cystoprostatectomy in Young Men With Bladder Cancer. *Urology*, **2016**, 94, 259-64	1.6	6
44	How accurately can MRI detect indolent disease?. *Current Opinion in Urology*, **2014**, 24, 264-9	2.8	5
43	Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2200193	2.2	5
42	Magnetic resonance microscopy may enable distinction between normal histomorphological features and prostate cancer in the resected prostate gland. *BJU International*, **2017**, 119, 414-423	5.6	4
41	Words of wisdom. Re: Improving detection of clinically significant prostate cancer: MRI/TRUS fusion-guided prostate biopsy. *European Urology*, **2014**, 65, 1218-9	10.2	4
40	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. *European Urology Oncology*, **2019**, 2, 333-336	6.7	4
39	Outcomes after salvage radical prostatectomy and first-line radiation therapy or HIFU for recurrent localized prostate cancer: results from a multicenter study. *World Journal of Urology*, **2019**, 37, 1491-1498	4	3
38	Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. *Journal of Urology*, **2021**, 205, 1361-1371	2.5	3

37	Contribution of serum anti-Müllerian hormone in the management of azoospermia and the prediction of testicular sperm retrieval outcomes: a study of 155 adult men. *Basic and Clinical Andrology*, **2021**, 31, 15	2.8	3
36	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. *BJU International*, **2021**, 127, 96-107	5.6	3
35	Pre-biopsy MRI as an adjunct for cancer detection in men with elevated PSA and no previous biopsy. *Translational Andrology and Urology*, **2017**, 6, 387-394	2.3	2
34	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 781.e17-781.e24	2.8	2
33	Impact of age on bladder cancer management practices: a general population study. *Acta Oncologica*, **2020**, 59, 462-466	3.2	1
32	Re: Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes. *European Urology*, **2018**, 74, 396	10.2	1
31	Re: Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy. *European Urology*, **2017**, 71, 301	10.2	1
30	Word of wisdom. Re: three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. *European Urology*, **2010**, 58, 941-2	10.2	1
29	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.. *European Urology Open Science*, **2022**, 35, 59-67	0.9	1
28	ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).. *Journal of Clinical Oncology*, **2019**, 37, 5048-5048	2.2	1
27	Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.. *Journal of Clinical Oncology*, **2021**, 39, 102-102	2.2	1
26	Impact of positive vascular margins status after surgical resection of non-metastatic renal cell carcinoma with caval tumour thrombus: a propensity score multicentre study. *World Journal of Urology*, **2021**, 1	4	0
25	Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.. *Journal of Clinical Oncology*, **2020**, 38, 5547-5547	2.2	0
24	Artificial urinary sphincter implantation in non-neurogenic men: a place for out-patient surgery. *World Journal of Urology*, **2021**, 39, 3541-3547	4	0
23	Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial.. *Journal of Clinical Oncology*, **2022**, 40, 115-115	2.2	0
22	Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy. *European Urology Open Science*, **2022**, 41, 24-34	0.9	0
21	Re: Long-term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. *European Urology*, **2020**, 78, 112	10.2	
20	Editorial Comment. *Journal of Urology*, **2018**, 200, 1121	2.5	

19	Role of Imaging as an Adjunct or Replacement for Biopsy: European Experience **2013**, 337-349	
18	Surgical Anatomy of the Prostate for Radical Prostatectomy **2013**, 187-198	
17	Bases histopathologiques de la thérapie focale dans le cancer localisé de la prostate. *Progrès En Urologie - FMC*, **2010**, 20, F96-F100	0
16	What are the survival outcomes for prostate cancer in a population-based cohort of unscreened men?. *Nature Reviews Urology*, **2005**, 2, 592-3	
15	Editorial Comment. *Journal of Urology*, **2020**, 204, 489	2.5
14	Qu'est-ce que le cancer de la prostate. *Bulletin De L'Academie Nationale De Medecine*, **2008**, 192, 1003-1012	0.1
13	Émergence de la simple surveillance du cancer de prostate et des traitements partiels. Rôle clé de l'IRM.. *Bulletin De L'Academie Nationale De Medecine*, **2018**, 202, 1049-1057	0.1
12	Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer.. *European Urology Open Science*, **2021**, 34, 27-32	0.9
11	Failure or Recurrence Management **2015**, 209-214	
10	TERRAIN.. *Journal of Clinical Oncology*, **2015**, 33, 5049-5049	2.2
9	Efficacy and safety of enzalutamide vs bicalutamide in European and North American men participating in the TERRAIN trial.. *Journal of Clinical Oncology*, **2016**, 34, 5063-5063	2.2
8	Focal Therapy for Anterior Cancers (Originated from Transition Zone). *Current Clinical Urology*, **2017**, 373-382	
7	Pathologic Rationale for Focal Therapy of Prostate Cancer: Elucidating Tumor Characteristics and Biology. *Current Clinical Urology*, **2017**, 85-104	
6	Surgical Anatomy of the Prostate **2018**, 163-175	
5	Localization of Cancer within the Prostate: Dynamic Contrast-Enhanced MRI55-65	
4	Pathologic Basis for Focal Therapy: Understanding Cancer Grade, Volume, and Spatial Location **2013**, 53-71	
3	Multimodality MRI-Guided Targeting **2013**, 133-140	
2	Reply by Authors. *Journal of Urology*, **2021**, 205, 1371	2.5

1 The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.. *Journal of Clinical Oncology*, **2021**, 39, 5071-5071 2.2